| Previous Close | 192.96 |
| Open | 192.00 |
| Volume | 756,989 |
| Avg. Volume (3M) | 1,272,693 |
| Market Cap | 15,079,237,632 |
| Price / Earnings (TTM) | 19.97 |
| Price / Earnings (Forward) | 13.53 |
| Price / Sales | 1.94 |
| Price / Book | 1.57 |
| 52 Weeks Range | |
| Earnings Date | 22 Oct 2025 |
| Profit Margin | 9.82% |
| Operating Margin (TTM) | 12.83% |
| Diluted EPS (TTM) | 9.71 |
| Quarterly Revenue Growth (YOY) | -4.80% |
| Quarterly Earnings Growth (YOY) | 24.50% |
| Total Debt/Equity (MRQ) | 37.12% |
| Current Ratio (MRQ) | 1.29 |
| Operating Cash Flow (TTM) | 1.16 B |
| Levered Free Cash Flow (TTM) | 901.28 M |
| Return on Assets (TTM) | 4.35% |
| Return on Equity (TTM) | 8.30% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Diagnostics & Research (US) | Bullish | Mixed |
| Diagnostics & Research (Global) | Bullish | Mixed | |
| Stock | ICON plc | Bearish | Bearish |
AIStockmoo Score
-0.1
| Analyst Consensus | -0.5 |
| Insider Activity | NA |
| Price Volatility | -1.0 |
| Technical Moving Averages | -1.0 |
| Technical Oscillators | 2.0 |
| Average | -0.13 |
|
Icon is a global late-stage contract research organization that provides drug development and clinical trial services to pharmaceutical, biotechnology, and medical-device firms. While the vast majority of its revenue comes from clinical research, Icon also offers ancillary services such as laboratory and imaging capabilities. The company is headquartered in Ireland. |
|
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Investment Style | Mid Core |
| % Held by Insiders | 0.63% |
| % Held by Institutions | 92.70% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 240.00 (Evercore ISI Group, 23.78%) | Buy |
| 240.00 (UBS, 23.78%) | Buy | |
| Median | 225.00 (16.05%) | |
| Low | 175.00 (Jefferies, -9.74%) | Hold |
| Average | 218.22 (12.55%) | |
| Total | 6 Buy, 3 Hold | |
| Avg. Price @ Call | 182.61 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Barclays | 02 Oct 2025 | 190.00 (-2.01%) | Hold | 192.96 |
| 25 Jul 2025 | 180.00 (-7.16%) | Hold | 187.01 | |
| Jefferies | 09 Sep 2025 | 175.00 (-9.74%) | Hold | 168.94 |
| Rothschild & Co | 03 Sep 2025 | 236.00 (21.72%) | Buy | 180.01 |
| Baird | 02 Sep 2025 | 224.00 (15.53%) | Buy | 177.84 |
| 24 Jul 2025 | 224.00 (15.53%) | Buy | 195.01 | |
| Citigroup | 21 Aug 2025 | 200.00 (3.15%) | Hold | 175.70 |
| Evercore ISI Group | 25 Jul 2025 | 240.00 (23.78%) | Buy | 187.01 |
| Mizuho | 25 Jul 2025 | 225.00 (16.05%) | Buy | 187.01 |
| Truist Securities | 25 Jul 2025 | 234.00 (20.69%) | Buy | 187.01 |
| UBS | 25 Jul 2025 | 240.00 (23.78%) | Buy | 187.01 |
| Show more | ||||
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 24 Sep 2025 | Announcement | ICON plc Schedules Third Quarter 2025 Earnings Conference Call |
| 04 Sep 2025 | Announcement | ICON Announces CEO Transition |
| 02 Sep 2025 | Announcement | ICON plc to Participate at Upcoming Investor Conferences |
| 23 Jul 2025 | Announcement | ICON Announces Results of Annual General Meeting |
| 23 Jul 2025 | Announcement | ICON Reports Second Quarter 2025 Results |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |